Chromadex Corp (NASDAQ: CDXC)’s stock price has gone rise by 10.03 in comparison to its previous close of 3.59, however, the company has experienced a 2.86% increase in its stock price over the last five trading days. Business Wire reported 2024-02-21 that LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex.
Is It Worth Investing in Chromadex Corp (NASDAQ: CDXC) Right Now?
The 36-month beta value for CDXC is also noteworthy at 1.98. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDXC is 44.60M, and at present, short sellers hold a 2.63% of that float. The average trading volume of CDXC on April 04, 2024 was 229.81K shares.
CDXC’s Market Performance
CDXC stock saw an increase of 2.86% in the past week, with a monthly gain of 137.95% and a quarterly increase of 176.22%. The volatility ratio for the week is 12.37%, and the volatility levels for the last 30 days are 14.53% for Chromadex Corp (CDXC). The simple moving average for the past 20 days is 44.85% for CDXC’s stock, with a 143.85% simple moving average for the past 200 days.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at 95.22% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.70% of loss for the given period.
Volatility was left at 14.53%, however, over the last 30 days, the volatility rate increased by 12.37%, as shares surge +128.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +188.32% upper at present.
During the last 5 trading sessions, CDXC rose by +2.86%, which changed the moving average for the period of 200-days by +136.53% in comparison to the 20-day moving average, which settled at $2.84. In addition, Chromadex Corp saw 176.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Gerber Brianna, who purchase 5,000 shares at the price of $1.41 back on Dec 01 ’23. After this action, Gerber Brianna now owns 27,436 shares of Chromadex Corp, valued at $7,050 using the latest closing price.
Jaksch Frank L Jr, the Director of Chromadex Corp, purchase 7,000 shares at $1.69 during a trade that took place back on Jun 12 ’23, which means that Jaksch Frank L Jr is holding 231,339 shares at $11,830 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.61 for the gross margin
The net margin for Chromadex Corp stands at -0.05. The total capital return value is set at -0.15. Equity return is now at value -17.29, with -9.06 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 2.15. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -13.72.
Currently, EBITDA for the company is -0.19 million with net debt to EBITDA at 6.11. When we switch over and look at the enterprise to sales, we see a ratio of 3.27. The receivables turnover for the company is 15.97for trailing twelve months and the total asset turnover is 1.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
In summary, Chromadex Corp (CDXC) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
